CD133+ colon cancer cells are more interactive with the tumor microenvironment than CD133-cells

Laboratory Investigation

Volumn 92, Issue 3, 2012, Pages 420-436

  Chao, Celia ^a,b   Carmical, J Russ ^a   Ives, Kirk L ^a   Wood, Thomas G ^a   Aronson, Judith F ^a   Gomez, Guillermo A ^a   Djukom, Clarisse D ^a   Hellmich, Mark R ^a,b  

^a University of Texas Medical Branch School of Medicine   (United States)

^b UNIVERSITY OF TEXAS MEDICAL BRANCH   (United States)

Author keywords

CD133; colon cancer; CXCR4; tumor microenvironment

Indexed keywords

BETA INTEGRIN; BETA8 INTEGRIN; CD133 ANTIGEN; CHEMOKINE RECEPTOR CXCR4; FIBROBLAST GROWTH FACTOR; FIBROBLAST GROWTH FACTOR RECEPTOR 2; MATRIGEL; STROMAL CELL DERIVED FACTOR 1; UNCLASSIFIED DRUG; VITRONECTIN;

AGED; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIGEN EXPRESSION; ARTICLE; CALCIUM CELL LEVEL; CANCER CELL; CANCER GROWTH; CARCINOGENICITY; CARCINOMA ASSOCIATED FIBROBLAST; CASE REPORT; CELL INTERACTION; COLONY FORMATION; COLORECTAL CANCER; CONTROLLED STUDY; EPITHELIUM CELL; FEMALE; FIBROBLAST; FLUORESCENCE ACTIVATED CELL SORTING; GENE EXPRESSION REGULATION; GENE IDENTIFICATION; HUMAN; HUMAN CELL; HUMAN TISSUE; MALE; MOUSE; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SCID MOUSE; STROMA; TUMOR MICROENVIRONMENT; TUMOR VOLUME;

EID: 84857721385     PISSN: 00236837     EISSN: 15300307     Source Type: Journal    
DOI: 10.1038/labinvest.2011.185     Document Type: Article

References (49)

1. Miraglia S, Godfrey W, Yin AH, et al. A novel five-transmembrane hematopoietic stem cell antigen: isolation, characterization, and molecular cloning. Blood 1997;90:5013-5021. (Pubitemid 28007218)
2. Yin AH, Miraglia S, Zanjani ED, et al. AC133, a novel marker for human hematopoietic stem and progenitor cells. Blood 1997;90:5002-5012. (Pubitemid 28007217)
3. Collins AT, Berry PA, Hyde C, et al. Prospective identification of tumorigenic prostate cancer stem cells. Cancer Res 2005;65: 10946-10951. (Pubitemid 41713363)
4. Hermann PC, Huber SL, Herrler T, et al. Distinct populations of cancer stem cells determine tumor growth and metastatic activity in human pancreatic cancer. Cell Stem Cell 2007;1:313-323. (Pubitemid 47355323)
5. Ma S, Chan KW, Hu L, et al. Identification and characterization of tumorigenic liver cancer stem/progenitor cells. Gastroenterology 2007;132:2542-2556. (Pubitemid 46890873)
6. Maw MA, Corbeil D, Koch J, et al. A frameshift mutation in prominin (mouse)-like 1 causes human retinal degeneration. Hum Mol Genet 2000;9:27-34. (Pubitemid 30145285)
7. O'Brien CA, Pollett A, Gallinger S, et al. A human colon cancer cell capable of initiating tumour growth in immunodeficient mice. Nature 2007;445:106-110. (Pubitemid 46067310)
8. Ricci-Vitiani L, Lombardi DG, Pilozzi E, et al. Identification and expansion of human colon-cancer-initiating cells. Nature 2007;445:111-115. (Pubitemid 46067311)
9. Richardson GD, Robson CN, Lang SH, et al. CD133, a novel marker for human prostatic epithelial stem cells. J Cell Sci 2004; 117:3539-3545. (Pubitemid 39206394)
10. Rutella S, Bonanno G, Procoli A, et al. Cells with characteristics of cancer stem/progenitor cells express the CD133 antigen in human endometrial tumors. Clin Cancer Res 2009;15:4299-4311.
11. Singh SK, Clarke ID, Terasaki M, et al. Identification of a cancer stem cell in human brain tumors. Cancer Res 2003;63:5821-5828. (Pubitemid 37187480)
12. Yin S, Li J, Hu C, et al. CD133 positive hepatocellular carcinoma cells possess high capacity for tumorigenicity. Int J Cancer 2007;120:1444-1450. (Pubitemid 46355378)
13. Ieta K, Tanaka F, Haraguchi N, et al. Biological and genetic characteristics of tumor-initiating cells in colon cancer. Ann Surg Oncol 2008;15:638-648. (Pubitemid 351643025)
14. Artells R, Moreno I, Diaz T, et al. Tumour CD133 mRNA expression and clinical outcome in surgically resected colorectal cancer patients. Eur J Cancer 2010;46:642-649.
15. Horst D, Kriegl L, Engel J, et al. CD133 expression is an independent prognostic marker for low survival in colorectal cancer. Br J Cancer 2008;99:1285-1289.
16. Yasuda H, Tanaka K, Saigusa S, et al. Elevated CD133, but not VEGF or EGFR, as a predictive marker of distant recurrence after preoperative chemoradiotherapy in rectal cancer. Oncol Rep 2009;22:709-717.
17. Du L, Wang H, He L, et al. CD44 is of functional importance for colorectal cancer stem cells. Clin Cancer Res 2008;14:6751-6760.
18. Horst D, Scheel SK, Liebmann S, et al. The cancer stem cell marker CD133 has high prognostic impact but unknown functional relevance for the metastasis of human colon cancer. J Pathol 2009;219:427-434.
19. Bhowmick NA, Neilson EG, Moses HL. Stromal fibroblasts in cancer initiation and progression. Nature 2004;432:332-337. (Pubitemid 39551661)
20. Tlsty TD, Coussens LM. Tumor stroma and regulation of cancer development. Annu Rev Pathol 2006;1:119-150.
21. Desmouliere A, Guyot C, Gabbiani G. The stroma reaction myofibroblast: a key player in the control of tumor cell behavior. Int J Dev Biol 2004;48:509-517. (Pubitemid 39360401)
22. Olumi AF, Grossfeld GD, Hayward SW, et al. Carcinoma-associated fibroblasts direct tumor progression of initiated human prostatic epithelium. Cancer Res 1999;59:5002-5011. (Pubitemid 29472907)
23. Orimo A, Gupta PB, Sgroi DC, et al. Stromal fibroblasts present in invasive human breast carcinomas promote tumor growth and angiogenesis through elevated SDF-1/CXCL12 secretion. Cell 2005;121:335-348. (Pubitemid 40692295)
24. Hwang RF, Moore T, Arumugam T, et al. Cancer-associated stromal fibroblasts promote pancreatic tumor progression. Cancer Res 2008;68:918-926. (Pubitemid 351206771)
25. Teicher BA, Fricker SP. CXCL12 (SDF-1)/CXCR4 pathway in cancer. Clin Cancer Res 2010;16:2927-2931.
26. Chao C, Tallman ML, Ives KL, et al. Gastrointestinal hormone receptors in primary human colorectal carcinomas. J Surg Res 2005;129:313-321. (Pubitemid 41797070)
27. Tsien RY, Harootunian AT. Practical design criteria for a dynamic ratio imaging system. Cell Calcium 1990;11:93-109. (Pubitemid 20095535)
28. Kalluri R, Zeisberg M. Fibroblasts in cancer. Nat Rev Cancer 2006;6: 392-401.
29. Bauer N, Fonseca AV, Florek M, et al. New insights into the cell biology of hematopoietic progenitors by studying prominin-1 (CD133). Cells Tissues Organs 2008;188:127-138. (Pubitemid 351962236)
30. Vermeulen L, Todaro M, de Sousa Mello F, et al. Single-cell cloning of colon cancer stem cells reveals a multi-lineage differentiation capacity. Proc Natl Acad Sci USA 2008;105:13427-13432.
31. Tot T. Cytokeratins 20 and 7 as biomarkers: usefulness in discriminating primary from metastatic adenocarcinoma. Eur J Cancer 2002;38:758-763. (Pubitemid 34280319)
32. Dalerba P, Dylla SJ, Park IK, et al. Phenotypic characterization of human colorectal cancer stem cells. Proc Natl Acad Sci USA 2007;104:10158-10163. (Pubitemid 47175279)
33. Levin TG, Powell AE, Davies PS, et al. Characterization of the intestinal cancer stem cell marker CD166 in the human and mouse gastrointestinal tract. Gastroenterology 2010;139:2072-2082 e2075.
34. Mori T, Doi R, Koizumi M, et al. CXCR4 antagonist inhibits stromal cellderived factor 1-induced migration and invasion of human pancreatic cancer. Mol Cancer Ther 2004;3:29-37. (Pubitemid 39193676)
35. Sutton A, Friand V, Brule-Donneger S, et al. Stromal cell-derived factor-1/chemokine (C-X-C motif) ligand 12 stimulates human hepatoma cell growth, migration, and invasion. Mol Cancer Res 2007;5:21-33.
36. Yang WL, Frucht H. Cholinergic receptor up-regulates COX-2 expression and prostaglandin E(2) production in colon cancer cells. Carcinogenesis 2000;21:1789-1793.
37. Dallas NA, Xia L, Fan F, et al. Chemoresistant colorectal cancer cells, the cancer stem cell phenotype, and increased sensitivity to insulin-like growth factor-I receptor inhibition. Cancer Res 2009;69:1951-1957.
38. Todaro M, Perez Alea M, Scopelliti A, et al. IL-4-mediated drug resistance in colon cancer stem cells. Cell Cycle 2008;7:309-313. (Pubitemid 351366493)
39. Takahashi S, Kamiyama T, Tomaru U, et al. Frequency and pattern of expression of the stem cell marker CD133 have strong prognostic effect on the surgical outcome of colorectal cancer patients. Oncol Rep 2010;24:1201-1212.
40. Zeelenberg IS, Ruuls-Van Stalle L, Roos E. The chemokine receptor CXCR4 is required for outgrowth of colon carcinoma micrometastases. Cancer Res 2003;63:3833-3839. (Pubitemid 36793074)
41. Mobley AK, Tchaicha JH, Shin J, et al. Beta8 integrin regulates neurogenesis and neurovascular homeostasis in the adult brain. J Cell Sci 2009;122:1842-1851.
42. Tomasini-Johansson BR, Sundberg C, Lindmark G, et al. Vitronectin in colorectal adenocarcinoma-synthesis by stromal cells in culture. Exp Cell Res 1994;214:303-312. (Pubitemid 24302406)
43. Vera PL, Iczkowski KA, Wang X, et al. Cyclophosphamide-induced cystitis increases bladder CXCR4 expression and CXCR4-macrophage migration inhibitory factor association. PLoS One 2008;3:e3898.
44. Kelly PN, Dakic A, Adams JM, et al. Tumor growth need not be driven by rare cancer stem cells. Science 2007;317:337. (Pubitemid 47106366)
45. Quintana E, Shackleton M, Sabel MS, et al. Efficient tumour formation by single human melanoma cells. Nature 2008;456:593-598.
46. Vermeulen L, De Sousa EMF, van der Heijden M, et al. Wnt activity defines colon cancer stem cells and is regulated by the microenvironment. Nat Cell Biol 2010;12:468-476.
47. Shmelkov SV, Butler JM, Hooper AT, et al. CD133 expression is not restricted to stem cells, and both CD133+ and CD133-metastatic colon cancer cells initiate tumors. J Clin Invest 2008;118:2111-2120.
48. Condeelis J, Pollard JW. Macrophages: obligate partners for tumor cell migration, invasion, and metastasis. Cell 2006;124:263-266. (Pubitemid 43121975)
49. Murdoch C, Muthana M, Coffelt SB, et al. The role of myeloid cells in the promotion of tumour angiogenesis. Nat Rev Cancer 2008;8:618-631.